TC-A 2317 hydrochloride

Cat. No.:	HY-103266
CAS No.:	1245907-03-2
Molecular Formula:	$C_{19}H_{29}ClN_6O$
Molecular Weight:	392.93
Target:	Aurora Kinase
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	TC-A 2317 hydrochloride is an orally active Aurora A kinase inhibitor (K_i=1.2 nM). TC-A 2317 hydrochloride exhibits excellent selectivity to Aurora B kinase (K_i=101 nM) and other 60 kinases, good cell permeability and good PK profile. Antitumor activity[1].

IC_{50} & Target	Aurora A	Aurora B
	1.2 nM (Ki)	101 nM (Ki)

In Vitro	TC-A 2317 hydrochloride (Compound 6) inhibits proliferation of HCT116 cells with an IC_{50} of 115 nM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	TC-A 2317 hydrochloride is effective in antitumor mice model without decrease of body weight[1]. TC-A 2317 hydrochloride shows good PK profile; C_{max} value is 4930 nM (T_{max}=1.2 h) and serum concentration after 24 h is 52 nM ($T_{1/2}$=3.3 h) at 30 mg/kg po in rats[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HCT-116 Xenograft mice mode[1]
Dosage:	P.o.; daily for 14 days
Administration:	30 mg/kg
Result:	Growth of tumor was inhibited by 59% after 14 days.

REFERENCES

[1]. Ando R, et al. 3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective Aurora A kinase inhibitors. Bioorg Med Chem Lett. 2010;20(15):4709-4711.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA